NMNH
CAS 108347-85-9
Purity≥95.0%
Reduced NMN material for NAD+ pathway screening
Reduced Nicotinamide Mononucleotide Powder (CAS 108347-85-9), specification ≥95.0%. NMNH is reduced nicotinamide mononucleotide, a reduced NAD precursor for formulation and research evaluation. Batch COA and evaluation samples are available. MOQ: 100 g. NAD+ ingredients
Quote / sample & delivery
Key Specifications
| Product Positioning | Reduced NMN material for NAD+ pathway screening |
| Application Scenarios | reduced nucleotide pathway research · redox formulation screening · analytical reference work |
| CAS Number | 108347-85-9 |
| Purity | ≥95.0% |
| Molecular Formula | C₁₁H₁₆N₂O₈P |
| Molecular Weight | 335.23 g/mol |
| Appearance | White to light yellow powder |
| Solubility | Soluble in water |
| Storage | ≤-20°C, inert atmosphere |
| Shelf Life | 18 months |
Procurement & delivery
Supply details confirmed by intended use, volume and target market
Reduced Nicotinamide Mononucleotide (NMNH, CAS 108347-85-9) is the dihydro (reduced) form of nicotinamide mononucleotide, a nucleotide that sits directly on the NAD+/NADH biosynthetic pathway. Its molecular formula is C11H16N2O8P with a molecular weight of 335.23 g/mol. Unlike its oxidized counterpart NMN, NMNH is not known to occur in appreciable amounts in common foods or tissues and is essentially a specialty biochemical obtained through targeted production rather than extraction. Commercial-scale material is typically manufactured via a biocatalytic route: a fermentation-derived, engineered enzyme from the Nudix pyrophosphatase family is used to selectively convert NADH into NMNH and AMP under mild aqueous reaction conditions, after which the product is purified by chromatography, concentrated under oxygen-limited conditions to protect its reduced state, and dried into a stable powder.
High-Purity, HPLC-Verified
Every batch is assayed at ≥95.0% purity by HPLC, ensuring consistent potency for both research and finished-product applications.
Enzymatic Biosynthesis, Tightly Controlled
Produced on a synthetic biology and enzymatic conversion platform with defined reaction, purification, and drying parameters for reliable batch-to-batch consistency.
Stable White to Light-Yellow Powder
Supplied as a free-flowing white to light yellow powder, packaged under oxygen-limited conditions to protect the reduced (NADH-type) structure during storage and transport.
Full Contaminant Screening
Each lot is screened for heavy metals (Pb, Hg, Cd, As) and microbial limits (total plate count, yeast/mold, E. coli, Salmonella) under an ISO-certified quality system.
Flexible Bulk & OEM Supply
Available in bulk quantities with support for OEM/private-label formulation, custom packaging sizes, and tailored documentation for supplement and research customers worldwide.
Test items, specifications and results for the listed batch are shown here. View or request a COA in the quality documents section.
Batch No.
PGNMNH-260512
Test date
2026-01-16
Specification
In-house
Pack size
1 kg/bag
Storage
≤-20°C, inert atmosphere
Conclusion
Conforms
| Test Item | Specification | Result |
|---|---|---|
| Appearance | Yellow powder | Complies |
| Identification | Retention time conforms to reference substance | Complies |
| Water | ≤10% | Complies |
| Purity | ≥95.0% | 98.3% |
| pH | 7.0–11.0 | 7.0 |
| Solubility | Soluble in water | Complies |
| Lead (Pb) | ≤0.5 ppm | Complies |
| Mercury (Hg) | ≤0.5 ppm | Complies |
| Cadmium (Cd) | ≤0.5 ppm | Complies |
| Arsenic (As) | ≤0.5 ppm | Complies |
| Total microbial count | ≤300 CFU/g | Complies |
| Coliforms | Not detected | Complies |
| Mold and yeast | ≤10 CFU/g | Complies |
| Staphylococcus aureus | Not detected | Complies |
| Salmonella | Not detected | Complies |
View an available COA in the quality documents section. Check the document for its product form and batch; request a signed COA for your purchasing or shipment batch separately.
Hard capsules
Tablets
Reduced NMNH is neither NMN nor a universal replacement for NADH; qualify identity and enzyme specificity first.
Complies
Water
98.3%
Purity
PGNMNH-260512 · Results apply to this lot; interpret purity, assay and water on their respective bases.
Composition candidates, processing sequences and tests support pilot design. Confirm candidate excipients and processes using this material in the actual finished formulation.
Application examples follow the materials, formats and findings actually studied. Combination studies, single-ingredient studies, commercial precedents and development candidates are distinguished.
NMNH is a reduced mononucleotide; NMN identity, concentrations and cellular responses are not interchangeable.
Show research and formulation insights +Hide details −Combination / selection rationale: NMNH is a reduced mononucleotide; NMN identity, concentrations and cellular responses are not interchangeable.
Published evidence / source details: A 2021 study found increased cellular/mouse NAD⁺ and NADH with NMNH, alongside suppressed glycolysis, TCA-cycle activity and cell growth, supporting evaluation beyond NAD⁺ alone.
Development insights: Use NMNH, oxidized NMN and vehicle controls across concentrations and times. Track material retention, NAD⁺/NADH, viability and metabolic endpoints, logging preparation-to-dosing time and oxygen exposure.
Evidence scope: Preclinical evidence, without a human potency multiplier or intake advice; the study synthesis does not replace this product’s process documentation.
2021 · NMNH metabolism study · DOI 10.1021/acs.jproteome.0c01037 ↗Cofactor panels help interpret redox changes, but NMNH needs its own chromatographic and response validation.
Show research and formulation insights +Hide details −Combination / selection rationale: Cofactor panels help interpret redox changes, but NMNH needs its own chromatographic and response validation.
Published evidence / source details: A 2018 study compared seven extraction conditions and identified NAD(H)/NADP(H) interconversion during preparation; it did not directly validate NMNH quantitation.
Development insights: Validate NMNH identity, peak separation and calibration with pre/post-extraction spikes and NMN controls. Record recovery, matrix effects and solution stability without borrowing other cofactors’ response factors.
Evidence scope: Adapts extraction-validation principles without claiming a validated NMNH method.
2018 · Redox-cofactor extraction · DOI 10.1089/ars.2017.7014 ↗NMN⁺/NMNH can be studied as a noncanonical cofactor pair, without assuming compatibility with ordinary NAD(P)-dependent enzymes.
Show research and formulation insights +Hide details −Combination / selection rationale: NMN⁺/NMNH can be studied as a noncanonical cofactor pair, without assuming compatibility with ordinary NAD(P)-dependent enzymes.
Published evidence / source details: A 2023 review covers growth-coupled engineering platforms including NMN⁺/NMNH. It summarizes engineered systems rather than a universal enzyme recipe.
Development insights: Compare cofactor selectivity with no-enzyme, no-substrate and inactivated-enzyme controls. Measure conversion, cofactor consumption and background oxidation; confirm product formation beyond a 340-nm signal.
Evidence scope: Engineered-enzyme candidate requiring target-system conversion and turnover measurements.
2023 · Growth-coupled enzyme-engineering review · DOI 10.1016/j.biotechadv.2023.108102 ↗Literature-Supported Research Directions
Cell and animal studies indicate that NMNH can increase NAD⁺ levels and alter NADH and glycolysis/TCA-related metabolites, supporting its value for NAD-metabolism research. The evidence is preclinical.
Citation: Liu et al., Journal of Proteome Research (2021): preclinical effects of NMNH on NAD⁺ and energy metabolism.View source
NMNH can be included in paired NAD⁺, NADH, NADP⁺ and NADPH analyses to study redox state, cofactor turnover and pathway changes. Sample extraction, light/oxygen exposure and assay design can affect results.
Citation: Lu et al. Extraction and Quantitation of Nicotinamide Adenine Dinucleotide Redox Cofactors. Antioxidants & redox signaling (2018). PMID: 28497978.View source
The reduced state of NMNH makes low-temperature, light-protected and oxygen-controlled screening especially relevant. Packaging, solution pH, dissolved oxygen and excipient compatibility should be confirmed through batch stability studies.
Citation: Liu et al. Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth. Journal of proteome research (2021). PMID: 33793246.View source
Note: For ingredient R&D and scientific information; findings depend on model, dose, formulation and population and do not constitute a treatment claim or efficacy guarantee.
Lead Time
3–5business days
Standard products are generally in stock; confirm the exact lead time with us.
Minimum Order
100 g
Samples, pilot trials, and commercial volumes are supported.
Foil Pouch
Sealed, moisture-protective inner packaging
Insulated Box + Carton
For products requiring temperature-controlled transport
Bulk Shipping
Palletized and stretch-wrapped for protection
Ambient storage: foil pouch + fiber drum; temperature controlled: foil pouch + insulated box/carton. Confirm by product.
Custom packaging: Custom foil bags or HDPE drums, GMP label printing, and export documentation are available. Contact us for a quote.Images are packaging illustrations.
Certifications
Biocatalyst Preparation via Fermentation
An engineered microbial strain expressing a Nudix-family NADH pyrophosphatase is cultivated by controlled fermentation, and the enzyme is harvested and prepared as the process biocatalyst.
Substrate (NADH) Preparation
Pharmaceutical-grade NADH, itself derived from fermentation-based NAD+ biosynthesis, is prepared as the starting substrate for the enzymatic conversion step.
Enzymatic Biotransformation
The purified pyrophosphatase selectively hydrolyzes the pyrophosphate bond of NADH under controlled pH and temperature in an aqueous reaction system, yielding NMNH and AMP in near-equimolar amounts.
Reaction Monitoring & Conversion Optimization
In-process HPLC monitoring tracks substrate conversion and byproduct formation, with reaction parameters adjusted to maximize NMNH yield while minimizing re-oxidation to NMN.
Chromatographic Separation
The reaction mixture is separated by ion-exchange and/or reverse-phase chromatography to isolate NMNH from AMP, residual NADH, and other process-related impurities.
Oxygen-Limited Concentration & Crystallization
The purified NMNH fraction is concentrated under low-oxygen, temperature-controlled conditions to prevent oxidative reversion to NMN, then crystallized or precipitated.
Drying & Micronization
Material is freeze-dried or vacuum-dried under inert gas protection, then milled and sieved to the target particle size for a free-flowing powder.
Quality Control & Oxygen-Protective Packaging
Finished powder is assayed by HPLC and tested for heavy metals and microbial limits, then packed under nitrogen or vacuum-sealed conditions to preserve the reduced form.
Purity is determined by reverse-phase HPLC with UV detection, comparing sample retention time and peak area against a qualified NMNH reference standard. Because NMNH is redox-sensitive and can slowly revert toward NMN under heat, light, or oxygen exposure, buyers should request a batch-specific certificate of analysis, confirm the assay date relative to shipment, and where relevant verify results with their own or a third-party laboratory before formulation.
NMNH is soluble in water, making it compatible with aqueous-based formulations such as powder blends, effervescent tablets, sublingual drops, and beverage premixes. Because the reduced form is more prone to oxidation than NMN, formulators are advised to minimize prolonged exposure to heat, light, and dissolved oxygen, consider near-neutral pH buffering, and evaluate the use of common antioxidant excipients or inert-gas processing to help preserve stability through manufacturing and shelf life.
Reduced nicotinamide mononucleotide (NMNH) powder has an HPLC purity specification of ≥95.0%. The lot COA records agreed quality items such as appearance, assay, loss on drying, heavy metals and microbiological limits. Review the offered batch documents before purchase.
NMNH is produced through a biocatalytic process built on our synthetic biology and enzymatic conversion platform. A Nudix-family pyrophosphatase enzyme selectively converts NADH (itself derived from fermentation-based NAD+ biosynthesis) into NMNH under mild aqueous conditions, followed by chromatographic purification, oxygen-limited concentration, and drying.
Yes, NMNH is soluble in water and works well in aqueous formulations. Because the reduced form is oxidation-sensitive, we recommend minimizing exposure to heat, light, and oxygen during processing and storage; our technical team can share general handling guidance on request.
Yes, small samples are available for quality evaluation, formulation trials, or third-party testing before you commit to a bulk purchase. Please contact our sales team with your intended application to arrange sample shipment.
Every batch is tested in-house under our internal quality management system, and we can coordinate third-party laboratory testing (e.g., for purity, heavy metals, or microbial limits) upon request, generally at the buyer's cost unless otherwise agreed.
Yes, we support OEM and private-label programs, including custom blends, capsule/tablet/powder formats, and branded packaging, for customers looking to bring finished NMNH products to market.
NMNH powder pack options are 100 g, 500 g, 1 kg. Special inner-packaging, labeling and transport requirements are agreed separately for the order.
The raw-material MOQ for NMNH powder is 100 g, with pack options of 100 g, 500 g, 1 kg. Packaging and transport for reduced NMNH should address moisture, oxygen exposure and light protection.
NMNH is reduced nicotinamide mononucleotide, distinct from oxidized NMN. Validate its own identity, chromatographic separation, response and solution stability. A NAD(P)(H) extraction panel does not automatically quantify NMNH. For cell studies, track redox cofactors and viability alongside NAD+ changes rather than interpreting a NAD+ rise alone as benefit.
Documents are subject to product and batch availability; third-party reports are provided only when applicable.
Quality documents
The specification sheet defines acceptance limits. The COA shows actual batch results, which may vary by batch. Third-party reports are provided only for products or batches that have been independently tested.
Stable acceptance criteria · Available on request
Actual test data · Check the COA for the applicable batch
Technical Resources
Related Products
NMN Powder (β-Nicotinamide Mononucleotide)
β-Nicotinamide Adenine Dinucleotide (NAD+) Powder
Nicotinamide Riboside Chloride Powder
Nicotinamide Riboside Hydrogen Malate Powder
Interested in NMNH?
Our R&D team will respond to your inquiry or sample request within 24 hours.
Scan to add WeChat
Alex Huang · Mon–Fri 9am–6pm CST
